Clinical trials: sponsored by Canadian Cancer Trials Group
NSCLC
Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer
This study is being done to answer the following question: What are the effects of new treatments on non-small cell lung cancer before surgery?
- Trial name
- NCT05714891
- Testing
- JDQ443
- Where
- 8 sites in Canada
- Volunteers
- 4 people
- Sponsor
- Canadian Cancer Trials Group
Non Small Cell Lung Cancer
Immune Checkpoint Blockade and Chemotherapy With or Without Fecal Microbiota Transplant in Advanced Non-Small Cell Lung Cancer
This study is being done to answer the following question: Can adding a treatment called Fecal Microbiota Transplant (FMT) to the usual treatment delay the growth or spread of cancer better than the usual treatment alone? FMT…
- Trial name
- LUNA-2 (NCT07890493)
- Testing
- LND101, Carboplatin (AUC 5 or 6), pemetrexed
- Volunteers
- 160 people
- Sponsor
- Canadian Cancer Trials Group
Cancer Metastatic
Stereotactic Body Radiotherapy vs Conventional Palliative Radiotherapy for Painful Non-Spine Bone Metastases
This study is being done to answer the following question: Is Stereotactic Body Radiation Therapy or SBRT (a form of radiation therapy which can deliver high doses of radiation to the specific painful area of the body most…
- Trial name
- NCT06391242
- Testing
- Standard Conventional Radiotherapy, Stereotactic Body Radiotherapy
- Where
- 12 sites in Canada
- Volunteers
- 230 people
- Sponsor
- Canadian Cancer Trials Group
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what…
- Conditions
- Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT07297667
- Testing
- Fludarabine, Cyclophosphamide, GCAR1
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
Multiple Myeloma
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Currently, daratumumab or isatuximab are given continuously (non-stop), along side lenalidomide, and dexamethasone as part of multiple myeloma treatment. are given continuously (non-stop).
- Trial name
- NCT06182774
- Testing
- Daratumumab, Lenalidomide, Dexamethasone
- Where
- 31 sites in Canada
- Volunteers
- 570 people
- Sponsor
- Canadian Cancer Trials Group
Endometrial Cancer
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
This protocol tests de-escalated adjuvant treatment in patients with POLE-mutated or p53wt/NSMP (p53 wildtype/no specific molecular profile) early-stage endometrial cancer (EC).
- Trial name
- NCT05640999
- Testing
- Vaginal brachytherapy, Adjuvant radiotherapy (EBRT +/- brachytherapy), Observation
- Where
- 123 sites in United States, Australia and 7 more
- Volunteers
- 393 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Head and Neck Cancer
Palliative Steroeotactic Body Radiotherapy vs Palliative Standard Radiotherapy in Patients With Advanced Head and Neck Cancer
This study is being done to answer the following question: Does stereotactic body radiation therapy (SBRT) provide better cancer control compared to standard radiation therapy (RT) for those with advanced head and neck cancer?
- Trial name
- NCT06641791
- Testing
- Standard Radiotherapy (SRT), Stereotactic Body Radiotherapy (SBRT)
- Where
- 10 sites in Canada
- Volunteers
- 196 people
- Sponsor
- Canadian Cancer Trials Group
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Economic Analysis of Early vs Delayed Therapy in Newly Diagnosed Asymptomatic High-Risk Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma:
Utilization data will be collected from all patients entered on the trial at Canadian centres from the time of registration until death, removal from study, or completion of 10 years of follow-up.
- Trial name
- NCT05371808
- Testing
- EQ-5D-5L Instrument, Work Productivity and Daily Activity Impairment (WPAI) survey, Resource Utilization Form (SMRC)
- Where
- 6 sites in Canada
- Volunteers
- 247 people
- Sponsor
- Canadian Cancer Trials Group
Cancer
Feasibility and Acceptability of Collecting Sociodemographic Data in CCTG Trials
This study is being done to answer the following question: Are patients on a clinical trial willing to provide answers to questions about their social, economic, and environmental factors-sometimes called social determinants of…
- Trial name
- FACTOR (NCT07390435)
- Testing
- Social Determinants of Health Questionnaire
- Where
- 15 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- Canadian Cancer Trials Group
Mantle Cell Lymphoma
Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell Therapy
The purpose of this study is to evaluate the effects of adding two oral medications (sonrotoclax plus zanubrutinib) to standard of care chimeric antigen receptor (CAR-T) cell therapy in participants with mantle cell lymphoma.
- Trial name
- NCT07341191
- Testing
- Zanubrutinib, Sonrotoclax, CAR-T Cell Therapy
- Where
- 5 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Canadian Cancer Trials Group
Lymphoma
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard…
- Trial name
- NCT02436707
- Testing
- Ibrutinib, Rituximab, Gemcitabine
- Where
- 11 sites in Canada
- Volunteers
- 129 people
- Sponsor
- Canadian Cancer Trials Group
Ovarian Cancer Prevention
ASA in Prevention of Ovarian Cancer (STICs and STONEs)
While ASA is not a cancer medication, research suggests that taking ASA reduces the probability of getting many types of cancer because of its anti-inflammatory action.
- Trial name
- NCT03480776
- Testing
- Acetylsalicylic acid
- Where
- 17 sites in Australia, Canada
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
CFI-400945 in Patients With Advanced/Metastatic Breast Cancer
The standard or usual treatment for this disease is to undergo chemotherapy to slow the spread of the disease and relieve some symptoms of cancer.
- Trial name
- NCT03624543
- Testing
- CFI-400945
- Where
- 6 sites in Canada
- Volunteers
- 51 people
- Sponsor
- Canadian Cancer Trials Group
Carcinoma
Canadian Initiative to Measure, Predict and Assess Cancer Treatment Outcomes in Patients Treated With Immuno-Oncotherapeutics
The researchers doing this study are interested in doing the following: Biomarker research using fresh tumour tissue and normal blood cells, and if required, tumour tissue already collected.
- Trial name
- (CAN-IMPACT-IO (NCT06630273)
- Volunteers
- 120 people
- Sponsor
- Canadian Cancer Trials Group
Cancer
A Phase II Study of Durvalumab Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (+/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studies
I238A: The purpose of this study is to find out what effects being treated with durvalumab has on cancer. The researchers doing this study also want to evaluate if prednisone (a type of steroid), when given together with…
- Trial name
- NCT03847649
- Testing
- Durvalumab, Prednisone, Tremelimumab
- Where
- 11 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Canadian Cancer Trials Group
Acute Leukemia
Emotion and Symptom-Focused Engagement Trial for Individuals With Acute Leukemia
The purpose of this study is to find out whether a novel manualized intervention, called Emotion and Symptom-focused Engagement (EASE), that combines psychological support with symptom screening plus triggered referral to early…
- Trial name
- EASE (NCT04224974)
- Testing
- Usual Care, EASE-psy
- Where
- 6 sites in Canada
- Volunteers
- 266 people
- Sponsor
- Canadian Cancer Trials Group
Melanoma
LND101 for Fecal Microbiota Transplantation in Combination With Immune Checkpoint Blockade in Advanced Melanoma
This study is being done to answer the following question: Can the chance of melanoma growing or spreading be lowered by receiving a treatment called LND101 for Fecal Microbiota Transplant (FMT) in addition to the usual…
- Trial name
- Canbiome2 (NCT06623461)
- Testing
- Standard of Care Immune Checkpoint Blockade, LND101
- Where
- 15 sites in Canada
- Volunteers
- 128 people
- Sponsor
- Canadian Cancer Trials Group
Non-hodgkin Lymphoma
Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
This study is being done to answer the following question: Can the addition of a new drug to the usual treatment lower the chance of primary central nervous system lymphoma growing or spreading? This study is being done to find…
- Trial name
- NCT05998642
- Testing
- Methotrexate, Rituximab (where available), Ibrutinib
- Where
- 8 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
Non-Small Cell Lung Cancer
Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC
The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.
- Trial name
- NCT02273375
- Testing
- MEDI4736
- Where
- 271 sites in United States, Australia and 17 more
- Volunteers
- 1,415 people
- Sponsor
- Canadian Cancer Trials Group
Lung Cancer Metastatic
Durvalumab and Tremelimumab ± Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC
Durvalumab is a new type of drug for many kinds of cancer. It is considered "immunotherapy" and not "chemotherapy". Laboratory tests show that it works by allowing the immune system to detect cancer and reactivate the immune…
- Trial name
- NCT03057106
- Testing
- Durvalumab, Tremelimumab, Platinum-Based Drug
- Where
- 49 sites in Australia, Canada
- Volunteers
- 301 people
- Sponsor
- Canadian Cancer Trials Group